Memantine in the Treatment of Executive Function Deficits in Adults With ADHD: A Pilot-Randomized Double-Blind Controlled Clinical Trial

Joseph Biederman, Ronna Fried, Laura Tarko, Craig Surman, Thomas Spencer, Amanda Pope, Rebecca Grossman, Katie McDermott, K. Yvonne Woodworth, Stephen V. Faraone

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Objective: To evaluate the efficacy and safety of memantine hydrochloride as an adjunct to stimulant pharmacotherapy for treating executive function deficits (EFDs) in adults with ADHD. Method: This was a 12-week, double-blind, placebo-controlled, randomized clinical trial of memantine added to open-label treatment with stimulant medication. Because of the small sample size, we considered a standardized mean difference (equivalent to effect size) of ≥0.5 and odds ratios ≥2 as indicators of trend improvements. Results: Twelve participants received memantine and 14 received a placebo. Trend improvements favoring memantine were observed on Behavior Rating Inventory of Executive Functions–Adult Inhibition and Self-Monitor subscales when compared with Placebo. No significant changes were noted on the Cambridge Neuropsychological Test Automated Battery. Conclusion: Among adults with ADHD and EFDs, adjunct treatment with memantine to osmotic release oral system-methylphenidate (OROS-MPH) was associated with improvements in selective areas of executive functioning, supporting the need for further research.

Original languageEnglish
Pages (from-to)343-352
Number of pages10
JournalJournal of Attention Disorders
Volume21
Issue number4
DOIs
StatePublished - Feb 2017
Externally publishedYes

Keywords

  • ADHD
  • adult
  • adult ADHD treatment
  • executive function deficits
  • memantine

Fingerprint

Dive into the research topics of 'Memantine in the Treatment of Executive Function Deficits in Adults With ADHD: A Pilot-Randomized Double-Blind Controlled Clinical Trial'. Together they form a unique fingerprint.

Cite this